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Overlapping  morphological  characteristics  pose some  difﬁculties  in  making  a proper  diag-
nosis  of  clear  cell  renal  cell carcinoma  (CCRCC),  chromophobe  renal  cell  carcinoma  (ChRCC),
and oncocytoma,  on  the basis  of hematoxylin–eosin-stained  tissue  sections.  Our  objective
was  to ﬁnd  out  a  fast,  reliable  panel  of  immunohistochemical  markers  for  differentia-
tion  between  them.  The  study  was  carried  out  on  55  selected  renal  tumor  specimens:
36  cases  of  CCRCC,  seven  cases  of ChRCC,  and  12  cases  of oncocytoma.  The  specimens
were  stained  immunohistochemically  for vimentin,  CD117,  cytokeratin  (CK)7,  and  caveolin
(Cav)-1. Sensitivity  and  speciﬁcity  for each  marker  were  calculated.  Vimentin  expression
was  exclusively  observed  in CCRCC  (100%)  and  negative  in ChRCC  and  oncocytoma.  CD117
was absent  in  CCRCC,  but  it was  strongly  expressed  in  ChRCC  (85.5%)  and oncocytoma
(91.7%),  with  high  sensitivity  and  speciﬁcity.  Most  CCRCCs  and  oncocytomas  were  negative
for  CK7  (91.7%  and  83.3%,  respectively),  in contrast  to  ChRCCs,  which  showed  positivity  in
nearly 86%  of  the  cases.  Good  sensitivity  and  speciﬁcity  were  calculated  for CK7  in differ-
entiating  studied  oncocytic  tumors.  Cav-1  was  positive  in ∼78%  of the CCRCCs  and  in  all
ChRCCs,  whereas  the  vast  majority  of  oncocytomas  were  negative.  So  the  immunoproﬁle
of  CCRCC  was  vimentin+/CD117−/CK7−/Cav-1±, ChRCC  was  vimentin−/CD117+/CK7+/Cav-
1+, and  oncocytoma  was  vimentin−/CD117+/CK7±/Cav-1−. So,  by using  combination  of
four  markers  (vimentin,  CD117,  CK7,  and  Cav-1),  we achieved  excellent  sensitivity  and
speciﬁcity  for  differential  diagnosis  of CCRCC,  ChRCC  and  oncocytoma.
©  2016  Saudi  Society  of Microscopes.  Published  by Elsevier  Ltd.  This  is  an open  access
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Renal cell carcinoma (RCC) is a common urological
umor and accounts for ∼3% of all human malignancies.
t has been shown to have a signiﬁcantly greater increase
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in incidence and mortality than other tumors of the geni-
tourinary tract [1,2].
Tumor characteristics such as tumor stage and grade
seem to have limited value in predicting the clinical out-
come of individual patients, as ∼50% of patients who
undergo surgery with curative intent for less-advanced dis-. Diagnostic utility of vimentin, CD117, cytokeratin-7 and
ma, chromophobe renal cell carcinoma and oncocytoma.
016.07.005
ease can be expected to develop a distant recurrence [3].
Moreover, RCC is a heterogeneous disease, comprised
of different histological variants with a distinct clinical
course, genetics, and response to treatment [4].
d. This is an open access article under the CC BY-NC-ND license
 ING Model
f MicrosARTICLEJMAU-112; No. of Pages 7
2 S.H. El-Shorbagy, H.A. Alshenawy / Journal o
Clear cell renal cell carcinoma (CCRCC) is overwhelm-
ingly the most common type of renal cancer, accounting for
70% of cases [5,6]. The World Health Organization deﬁnes
CCRCC as “a malignant neoplasm composed of clear or
eosinophilic cytoplasmic cells arranged within a delicate
distinct vascular network” [6].
Chromophobe renal cell carcinoma (ChRCC) is a type
of malignant renal epithelial tumor, accounting for ∼5%
of renal cancer, including classic, eosinophilic, and mixed
variants. Classic type of ChRCC is composed mainly of
pale cells with “soap bubble” appearance of the cytoplasm.
The eosinophilic variant (containing > 80% eosinophilic
cells) has nested, alveolar, or sheet-like architecture with
eosinophilic granularity, perinuclear clearing, and periph-
eral accentuation of cytoplasm, which may  mimic  renal
oncocytoma in many circumstances. The mixed variant
ChRCC contains a mixture of pale and eosinophilic cells [7].
Oncocytoma is a benign renal tumor. It can frequently
be confused with ChRCC, because it consists of nests
of neoplastic oncocytic cells. These are rounded, well-
differentiated, neoplastic cells with intensely eosinophilic
granular cytoplasm as a result of a large number of
mitochondria and have round regular nuclei [8].
Accurate classiﬁcation of renal neoplasms is important
not only for its correlation with the cytogenetic ﬁndings,
but more importantly for its prognostic signiﬁcance. The
outcome for patients with ChRCC generally is better than
for those with CCRCC [9], but worse than for renal oncocy-
toma, of which the overwhelming majority are benign and
do not metastasize [10,11].
One of the diagnostic criteria of ChRCC is Hale colloidal
iron [12], and another is intracytoplasmic microvesicles
observed by electron microscopy [13], but the eosinophilic
variant of ChRCC is particularly difﬁcult to distinguish from
renal oncocytoma and CCRCC [14].
Owing to the overlapping morphological characteris-
tics, separation of CCRCC and ChRCC from oncocytoma
based on conventional hematoxylin and eosin (H&E) stain-
ing is often challenging, even in the hands of experienced
pathologists [15,16]. Immunohistochemistry is available in
most pathology laboratories and is technically easier to
perform and interpret than Hale colloidal iron and electron
microscopy [14].
Vimentin, a major constituent of the intermediate
ﬁlament family of proteins, is expressed in normal mes-
enchymal cells and is known to maintain cellular integrity
[17].
CD117 is a transmembrane tyrosine kinase receptor
protein that plays a role in intracellular signal transduc-
tion in several cell types. It regulates apoptosis and cell
differentiation and proliferation. It is well known that KIT
pathological activation through mutations may  lead to neo-
plasia [18].
Cytokeratin (CK)7 belongs to the neutral basic type II
subfamily of cytokeratins of low molecular weight [19].
CK7 has been reported in many adenocarcinomas, such as
breast, endometrium, ovaries, and thyroid, as well as inPlease cite this article in press as: El-Shorbagy SH, Alshenawy HA
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carcinoma of the bladder [20].
Caveolin (Cav)-1, a scaffolding protein, has important
roles in many cellular functions, including transport-
ing cholesterol and glycosphingolipids, sequestrating and PRESS
copy and Ultrastructure xxx (2016) xxx–xxx
organizing many signaling molecules, and regulating some
kinase activities [21]. Also, it participates in the adjust-
ment of endothelial cell differentiation and angiopoiesis,
and plays an important role in tumor advancement [22].
Vimentin and CK7 are useful in differentiating ChRCC
from oncocytoma according to most investigators, but
conﬂicting results have been reported [23].
In recent years, other studies have suggested that CD117
[24,25] and Cav-1 [21] can be also valuable for differentia-
tion. However, no single marker appears to be sufﬁciently
accurate by itself [14].
Accordingly, we examined the speciﬁc staining patterns
of four markers (vimentin, CD117, CK7, and Cav-1) using
immunohistochemistry for distinguishing oncocytic renal
neoplasms including CCRCC, ChRCC, and oncocytomas.
2. Materials and methods
2.1. Case selection and tissue specimens
This work was approved by the Ethical Committee of
the Faculty of Medicine, Tanta University, Tanta, Egypt.
The present study included 55 selected renal tumor cases:
36 cases of CCRCC, seven cases of eosinophilic variant of
ChRCC, and 12 cases of oncocytoma, from the pathology
records archives of Tanta University. All specimens were
obtained by radical or partial nephrectomy. Cases with nee-
dle biopsies were excluded. Parafﬁn sections of 4–5 m
thickness were stained with H&E to conﬁrm their histo-
logical diagnosis.
2.2. Immunohistochemical staining of the studied cases
Immunohistochemistry was performed on formalin-
ﬁxed, parafﬁn-embedded 4-mm-thick sections mounted
on positively charged slides. Tissue sections were deparaf-
ﬁnized and rehydrated in graded alcohols to distilled water,
then they were incubated in 3% hydrogen peroxide for
10 minutes to block the endogenous peroxidase. Slides
were immersed in acetic acid and heated in a microwave at
95 ◦C for 30 minutes for antigen retrieval; left to cool down
at room temperature and rinsed with phosphate-buffered
saline; and incubated overnight at room temperature with
the following primary antibodies: vimentin (V9 mono-
clonal, 1:500; Dako, Carpinteria, CA, USA); CD117 (clone:
A4502, 1:200; Dako); CK7 (K72.7 monoclonal, 1:50; Bio-
care, California, USA) and Cav-1 (rabbit monoclonal E249,
1:250, Novus Biologicals, Littleton, CO, USA).
The staining was  completed using the streptavidin–
biotin complex (Dako Envision System). 3,3′-
Diaminobenzidine was  applied for 10–15 minutes and
the reaction was stopped using distilled water. Counter
staining with hematoxylin was applied for 2 minutes and
washed with distilled water. Appropriate positive and
negative controls were included in each run. The slides of
negative controls were prepared by excluding the primary
antibody and replacing it with phosphate-buffered saline.. Diagnostic utility of vimentin, CD117, cytokeratin-7 and
ma, chromophobe renal cell carcinoma and oncocytoma.
016.07.005
As regards vimentin, CD117, and CK7, tumor cells were
considered positive only when the appropriate staining
pattern was  noted (vimentin gives cytoplasmic stain-
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ytoplasmic staining with membranous accentuation). The
xtent of immunoreactivity was performed by analyzing
he extent of the staining positivity among tumor cells.
he score of these markers was as follows: 0 or negative
 5% tumor cell positivity; +1 < 10% tumor cell positivity;
2 (focal) = 10–50% tumor cell positivity; and +3 (diffuse) >
0% tumor cell positivity. Scores 0 and 1 were considered
egative, and cytoplasmic CK7 staining without membra-
ous accentuation was considered negative [14].
Cav-1 expression was based on the presence of cytoplas-
ic  and/or membranous staining and positive staining of
he endothelium provided an internal positive control for
av-1 immunostaining. Cav-1 was scored into three cate-
ories (0 = negative, +1 (focal) < 20%, and +2 (diffuse) ≥ 20%)
21].
.3. Statistical analysis
The sensitivity and speciﬁcity were calculated for each
arker [26].
Sensitivity (also called the true-positive rate) measured
he proportion of positives that were correctly identiﬁed as
uch.
ensitivity
= ,Number of true positives-Number of true positives
+ number of false negatives (1)
Speciﬁcity (also called the true-negative rate) measured
he proportion of negatives that were correctly identiﬁed
s such.
peciﬁcity
= ,Number of true negatives-Number of true negatives
+ number of false positives (2)
. Results
.1. Histopathological and immunohistochemical results
f the studied cases
The present study included 55 selected oncocytic renal
umor cases: 36 were CCRCC, seven were eosinophilic vari-
nt of ChRCC, and 12 were oncocytoma (Table 1). CCRCC
howed a solid, nesting, and tubular pattern of growth with
osinophilic cytoplasm embedded in a delicate vascular
etwork (Figure 1A). ChRCC comprised large vegetable-
ike polygonal cells with eosinophilic cytoplasm, irregular
uclei, perinuclear clear halo, and prominent cell mem-
rane (Figure 1B). Renal oncocytomas were composed
xclusively of oncocytes that were arranged in nests or
lveoli separated from each other by loose ﬁbrous stroma
Figure 1C).Please cite this article in press as: El-Shorbagy SH, Alshenawy HA
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Vimentin showed diffuse cytoplasmic expression in
ll 36 CCRCCs, with 80–100% positivity in tumor cells
Figure 2A). It was absent in all seven ChRCCs (Figure 2B)
nd all 12 oncocytomas (Figure 2C). PRESS
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CD117 was  absent in CCRCCs (Figure 3A). It was  strongly
expressed in six of seven (85.8%) ChRCCs (Figure 3B) and
11 of 12 (91.7%) oncocytomas, with diffuse staining in
almost all positive cases (Figure 3C). The staining was
complete–membranous (Figure 3).
Most CCRCCs (33/36) were negative for CK7 (Figure 4A),
of which, three showed only cytoplasmic staining without
distinct membrane accentuation and were considered neg-
ative. CK7 was positive in six of seven ChRCCs (Figure 4B),
whereas 10 of 12 (83.3%) renal oncocytomas were negative
(Figure 4C), of which, two  (16.7%) showed few scattered
immunoreactivity in < 10% of tumor cells and were consid-
ered negative. The two CK7-positive oncocytomas showed
focal reactivity in < 50% of tumor cells.
Cav-1 was expressed in 28/36 (78%) CCRCCs (Figure 5A),
and in all seven ChRCCs (Figure 5B), whereas the vast
majority of oncocytomas were negative (Figure 5C). Only
one case of oncocytoma out of 12 showed focal positivity
for Cav-1 in < 20% of tumor cells (1+) (Figure 5).
3.2. Sensitivity and speciﬁcity of studied markers in
diagnosis of selected cases
Evaluation of the sensitivity and speciﬁcity of vimentin
in diagnosis of CCRCC showed that vimentin was  sensitive
and speciﬁc for diagnosis of CCRCC (both 100%; Table 1).
CD117 showed 89.5% sensitivity and 100% speciﬁcity in
diagnosis of both ChRCC and oncocytoma and exclusion
of CCRCC. CK7 showed 85.5% sensitivity and speciﬁcity for
ChRCC, and lastly, Cav-1 showed 100% sensitivity and 91.7%
speciﬁcity for diagnosis of ChRCC when compared to onco-
cytoma.
4. Discussion
RCC accounts for 2–3% of all new cancers diagnosed
and 85% of all primary renal neoplasms in adults [2]. Adult
renal epithelial neoplasms are a heterogeneous group com-
prised of subtypes that have distinct gross, histological,
ultrastructural, and immunohistochemical features. Thus,
classiﬁcation of renal cell neoplasms is important from the
treatment and prognosis point of view as well as for under-
standing their histogenesis, and molecular and cytogenetic
behavior that allow further improvement in their manage-
ment [27].
The most common subtype in the present study was
CCRCC, accounting for 84% of malignant cases of RCC, simi-
lar to previous ﬁndings of Vera-Badillo et al [28]. The other
studied subtype of RCC was  ChRCC, which accounts for 16%
of malignant cases, as previously reported by Pan et al [24].
Similarly, Vera-Badillo et al [28] showed that ChRCC com-
prised 5–10% of their total cases of RCC. We  found that
renal oncocytoma comprised 21.8% (n = 12) of total studied
cases in contrast to the ﬁnding of Pradhan et al [27], who
showed that, among the total cases they examined, CCRCC
was the most common tumor with 74.8%, ChRCC was  7.9%,
and oncocytoma was  only 1.8%.. Diagnostic utility of vimentin, CD117, cytokeratin-7 and
ma, chromophobe renal cell carcinoma and oncocytoma.
016.07.005
The separation of different subtypes of oncocytic
renal neoplasms (CCRCC, ChRCC, and oncocytoma) using
ordinary H&E remains problematic in some cases. This
prompted us to explore a set of immunohistochemical
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Table 1
Immunohistochemical results of oncocytic renal cell tumors.








































































(N  = 55)
36 (65.5) 7 (12.7) 12 (21.8)
Cav-1=caveolin-1; CCRCC=clear cell renal cell carcinoma; ChRCC=chromophobe renal cell carcinoma; CK7=cytokeratin-7.
Fig. 1. (A) Clear cell renal cell carcinoma showing solid, nesting, and tubular pattern of growth with eosinophilic cytoplasm in delicate vascular network.
(B)  Chromophobe renal cell carcinoma composed of large vegetable-like polygonal cells with eosinophilic cytoplasm, irregular nuclei, perinuclear clear
halo,  and prominent cell membrane. (C) Renal oncocytomas composed of oncocytes that are arranged in nests or alveoli separated by loose ﬁbrous stroma
(hematoxylin and eosin, 400×).
vimenti
expressiFig. 2. (A) Clear cell renal cell carcinoma showing diffuse cytoplasmic 
expression of vimentin; and (C) oncocytoma showing negative vimentin 
markers that would improve the accuracy of diagnosis,
as reliance on a single marker in differential diagnosis ofPlease cite this article in press as: El-Shorbagy SH, Alshenawy HA
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tumors with overlapping morphology may  be insufﬁcient
or even misleading, especially when the interpretation of
the stain is not straightforward or the tissue sample is
small.n expression; (B) chromophobe renal cell carcinoma showing negative
on (Avidin Biotin Complex, 400×).
Accordingly, the objective of this study was to iden-
tify the speciﬁc staining patterns of four studied markers. Diagnostic utility of vimentin, CD117, cytokeratin-7 and
ma, chromophobe renal cell carcinoma and oncocytoma.
016.07.005
(vimentin, CD117, CK7, and Cav-1) in three different types
of oncocytic renal tumor (CCRCC, ChRCC, and oncocytoma),
to determine an optimal diagnostic strategy for differenti-
ation.
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Fig. 3. (A) Negative expression of CD117 in clear cell renal cell carcinoma. (B) CD117 was strongly diffusely positive in chromophobe renal cell carcinoma
and  (C) oncocytoma. The staining was complete–membranous (Avidin Biotin Complex, 400×).
Fig. 4. (A) Negative expression of cytokeratin-7 (CK7) in clear cell renal cell carcinoma. (B) CK7 was positive in chromophobe renal cell carcinoma, and (C)














sig. 5. (A) Caveolin-1 was  positively expressed in clear cell renal cell car
hereas (C) oncocytoma was  negative (Avidin Biotin Complex, 400×).
Our results showed that vimentin was only positive in
CRCC, whereas all ChRCCs and oncocytomas were neg-
tive with 100% sensitivity and speciﬁcity. Such ﬁndings
oincided with those of Bazille et al [29], who found that
imentin was only positive in CCRCC, whereas all cases
f ChRCC and oncocytoma were negative. However, other
eports showed vimentin positivity varied from 54.5% to
5% in CCRCC [15,27]. A few studies have documented
imentin positivity in 20% of ChRCCs [14,27] and 9.7% ofPlease cite this article in press as: El-Shorbagy SH, Alshenawy HA
caveolin-1 in differentiation between clear cell renal cell carcino
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ncocytomas [30]. These discrepancies could be related to
he variance in pathological diagnosis, use of different anti-
odies and reagents for the studies, and different laboratory
taining procedures, as previously reported by Liu et al [14]. with score 2 and (B) in chromophobe renal cell carcinoma with score 2,
The diagnosis of ChRCC or oncocytoma should be rendered
with caution if diffuse vimentin staining is detected.
The present study showed CD117 expression in nearly
86% of ChRCCs and 92% of oncocytomas, in contrast to neg-
ative staining in CCRCCs, with 89.5% sensitivity and 100%
speciﬁcity. Such ﬁndings coincided with those of Liu et al
[14], who showed that vimentin and CD117 each showed
100% speciﬁcity and high sensitivity (100% and 90%, respec-
tively), allowing separation of CCRCC from both ChRCC and. Diagnostic utility of vimentin, CD117, cytokeratin-7 and
ma, chromophobe renal cell carcinoma and oncocytoma.
016.07.005
oncocytoma. Also, Pan et al [24] found that 83% (24/29) of
ChRCCs and 71% (5/7) of oncocytomas had membranous
immunoreactivity for CD117, whereas all CCRCCs were
negative; similar to another study with 88% positivity in
ARTICLE IN PRESSG ModelJMAU-112; No. of Pages 7
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a
mophobFig. 6. Suggested strategy for diagnosis of CCRCC, ChRCC, and oncocytom
Cav-1 = caveolin-1; CCRCC =clear cell renal cell carcinoma; ChRCC = chro
ChRCC, 71% in oncocytoma, and 0% in CCRCC [31]. Wang and
Mills [32] observed 100% immunoreactivity with CD117
in both ChRCC and oncocytoma. Yamazaki et al [33] also
detected overexpression of CD117 in membranes of cells
of ChRCC, which ranged from 88% to 100% of tumor cells.
Most cases of ChRCC and oncocytoma in the current study
were positive for CD117 (85.8% and 91.7%, respectively),
thus, it could not be used in the differentiation between
them, but it could be used as a good marker for exclusion
of CCRCC.
Most CCRCCs and oncocytomas were negative for CK7
(91.7% and 83.3%, respectively), in contrast to ChRCCs,
which showed positivity in nearly 86% of the cases. The only
two positive cases of oncocytoma showed focal reactivity
in < 50% of the tumor cells. Good sensitivity and speciﬁcity
were calculated for CK7 in differentiating studied oncocytic
tumors (85.7% and 89.6%, respectively). Our results coin-
cided with those of Pradhan et al [27], who detected CK7
positivity in all cases of ChRCC, whereas all cases of CCR-
CCs and renal oncocytoma were negative. Also, Liu et al
[14] found that CK7 expression yielded 100% speciﬁcity and
86% sensitivity in differentiation between oncocytoma and
ChRCC. By contrast, Garcia and Li [21] detected CK7 posi-
tivity in all cases of ChRCC and in 96% of renal oncocytomas.
Cav-1 was immunohistochemically expressed in nearly
80% of cases of CCRCCs and in all ChRCCs cases, whereas the
vast majority of oncocytomas were negative (91.7%). The
single positive oncocytoma showed only focal reactivity for
Cav-1. Such ﬁndings coincided with Garcia and Li [21], who
detected 100% positivity in ChRCCs and 88% negativity in
oncocytomas.
The results of the current study showed that Cav-1 is
not useful in excluding CCRCC, as a large number of thesePlease cite this article in press as: El-Shorbagy SH, Alshenawy HA
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cases were positive. By contrast, when Cav-1 was  used for
differentiation between ChRCC and oncocytoma, it gave
excellent results with 100% sensitivity and 91.7% speci-
ﬁcity.e renal cell carcinoma; CK7 = cytokeratin-7.
Carrion et al [34] reported that oncocytoma had a higher
labeling index for Cav-1, compared with several types of
RCC, including four cases of ChRCC. These ﬁndings are
in sharp contrast with ours and could be attributed to
the method of immunohistochemical preparation. Tumors
might contain endogenous biotin and generate false posi-
tivity if an avidin–biotin detecting system is used without
blocking the endogenous biotin.
In conclusion, after the study of vimentin, CD117,
CK7, and Cav-1 immunohistochemical expression in onco-
cytic renal tumors, we suggest the diagnostic strategy
shown in Figure 6. The immunoproﬁle of CCRCC is
vimentin+/CD117−/CK7−/Cav-1±; ChRCC is vimentin−/
CD117+/CK7+/Cav-1+; and oncocytoma is vimentin−/
CD117+/CK7±/Cav-1−. So, the use of the panel of these four
markers is beneﬁcial in differentiating problematic cases of
oncocytic renal neoplasms(Figure 6).
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